Federated Hermes’s Akero Therapeutics AKRO Stock Holding History

Federated Hermes’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,584	Closed	-$167K	–	2090
2023 Q2	$167K	Sell	3,584 -54,420	-94%	-$2.49M	﹤0.01%	1571
2023 Q1	$2.22M	Sell	58,004 -20	-0%	-$892	0.01%	926
2022 Q4	$3.18M	Buy	+58,024	New	+$2.49M	0.01%	789
2022 Q3	–	Sell	-128,087	Closed	-$1.21M	–	2139
2022 Q2	$1.21M	Buy	128,087 +128,073	+914,807%	+$1.34M	﹤0.01%	1069
2022 Q1	$1K	Buy	+14	New	+$245	﹤0.01%	2056
2021 Q1	–	Sell	-32,830	Closed	-$847K	–	2213
2020 Q4	$847K	Sell	32,830 -5,787	-15%	-$161K	﹤0.01%	1385
2020 Q3	$1.19M	Buy	38,617 +38,538	+48,782%	+$1.35M	﹤0.01%	1178
2020 Q2	$2K	Buy	+79	New	+$1.8K	﹤0.01%	2072

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Federated Hermes's AKRO Position: Q3 2023 in Review

Federated Hermes sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 3,584 shares — an estimated $167K sold.

Federated Hermes first reported a position in AKRO in Q2 2020 and held it in 8 quarters. The position peaked at $3.18M in Q4 2022. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

Federated Hermes reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 3,584 Akero Therapeutics shares in Q3 2023, an estimated $167K.
Federated Hermes first reported a position in Akero Therapeutics in Q2 2020 and held it in 8 quarters.
Federated Hermes's Akero Therapeutics position peaked at $3.18M in Q4 2022.
181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.